Treatment of Depression in the Elderly

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00130455
Recruitment Status : Terminated
First Posted : August 15, 2005
Last Update Posted : February 6, 2007
Psychogeriatric Unit, CU Hospital, Frederiksberg
Amager Hospital
Psychiatric Center Ballerup
Geriatric Department,Korsør, Vestsjælland
Information provided by:
Psychiatric Hospital, Hillerod

Brief Summary:

The study is designed to establish the efficacy and tolerability of escitalopram in the treatment of depressive episodes of mild to moderate severity in the elderly.

The study is designed as a mainly naturalistic study including all patients of 65 years of age or above that judged by the clinician would benefit from treatment by an antidepressant medication. The study is designed as a double-blind, randomised placebo controlled study with two groups of active treatment (escitalopram in two doses, 5 or 10 mg daily) in a twelve week period.

Condition or disease Intervention/treatment Phase
Depression Drug: escitalopram Phase 4

Study Type : Interventional  (Clinical Trial)
Enrollment : 189 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double
Primary Purpose: Treatment
Official Title: A 12 Week Multi-Centre, Randomized, Double-Blind, Placebo Controlled Evaluation of the Most Efficacious and Tolerable Dose of Escitalopram in the Treatment of Elderly Patients
Study Start Date : April 2006
Study Completion Date : January 2008

Resource links provided by the National Library of Medicine

Primary Outcome Measures :
  1. Remission during the study is defined as a Hamilton 6-item depression subscale (HAM-D6) score less than or equal to 4
  2. Response will be defined as a drop in HAM-D6 score of 50% or more

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   65 Years and older   (Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • In- or out-patients of 65 years of age or above fulfilling the International Classification of Diseases-Tenth Edition (ICD-10) diagnosis of depressive single episode (F32.00-32.11. 32.8 or 32.9), depressive recurrent episode (F33.00-33.11, 33.8 or 33.9) or organic depressive episode (F06.32).
  • The depressive state should be mild to moderate and reach a score on HAM-D6 of ≥ 7 and ≤ 11
  • Patients with dementia can be included provided they have a mini mental state exam (MMSE) score of ≥ 17

Exclusion Criteria:

  • Patients with a current depressive episode of a severity reaching a score of ≥ 12 on the HAM-D6-item depression factor. This is to exclude patients with severe or psychotic depression
  • Patients with suicidal thoughts or behaviour
  • Patients with conditions where treatment with escitalopram is contraindicated: e.g. hypersensitivity to escitalopram or other contents of escitalopram tablets, concomitant treatment with non-selective, irreversible mono-amine-oxidase inhibitors, such as Marplan
  • Patients who in the current depressive episode have had a failed trial of treatment with escitalopram
  • Co-morbid dementia with a severity corresponding to a score on the MMSE of less than 17 as these patients will often be without the ability to give informed consent
  • Patients with sensory defects rendering psychometric assessment impossible, e.g. deafness, blindness, severe aphasia
  • Patients who cannot speak Danish well enough to make psychometric assessment possible and meaningful
  • Patients with congenital or early acquired intellectual deficits

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00130455

Alex Koerner
Hilleroed, Denmark, DK-3400
Sponsors and Collaborators
Psychiatric Hospital, Hillerod
Psychogeriatric Unit, CU Hospital, Frederiksberg
Amager Hospital
Psychiatric Center Ballerup
Geriatric Department,Korsør, Vestsjælland
Principal Investigator: Alex Koerner, MD Psychiatric hospital, Hilleroed, Denmark Identifier: NCT00130455     History of Changes
Other Study ID Numbers: HIL-01
First Posted: August 15, 2005    Key Record Dates
Last Update Posted: February 6, 2007
Last Verified: February 2007

Additional relevant MeSH terms:
Depressive Disorder
Behavioral Symptoms
Mood Disorders
Mental Disorders
Serotonin Uptake Inhibitors
Neurotransmitter Uptake Inhibitors
Membrane Transport Modulators
Molecular Mechanisms of Pharmacological Action
Neurotransmitter Agents
Serotonin Agents
Physiological Effects of Drugs
Antidepressive Agents, Second-Generation
Antidepressive Agents
Psychotropic Drugs
Antiparkinson Agents
Anti-Dyskinesia Agents
Autonomic Agents
Peripheral Nervous System Agents
Muscarinic Antagonists
Cholinergic Antagonists
Cholinergic Agents